Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2017

Open Access 01-02-2017 | short review

Milestones of the last 10 years

CNS cancer

Authors: Prof. Dr. Christine Marosi, a. Prof. Dr. Matthias Preusser

Published in: memo - Magazine of European Medical Oncology | Issue 1/2017

Login to get access

Summary

For neuro-oncologists, much was accomplished in the last decade, including the establishment of the first standard of care (SOC) in this field of oncology. New treatment options boosted research in the whole field of neuro-oncology, as well clinical trials, translational and basic research. Accumulated data on molecular–genetic subgroups with distinct clinical outcomes in disease entities led to the establishment of new biomarkers and to the collaborative formulation of a new WHO classification of central nervous system tumors.
Literature
1.
Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRefPubMed
2.
Lawrence YR, et al. Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer. 2012;118(17):4228–34.CrossRefPubMed
3.
Bauchet L, et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro-oncology. 2010;12(7):725–35.CrossRefPubMedPubMedCentral
4.
Louis DN, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–20.CrossRefPubMed
5.
Malzkorn B, Reifenberger G. Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016. Curr Opin Oncol. 2016;28(6):494–501.CrossRefPubMed
6.
7.
Esteller M, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350–4.CrossRefPubMed
8.
Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.CrossRefPubMed
9.
Gilbert MR, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085–91.CrossRefPubMedPubMedCentral
10.
Nabors LB, et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro-oncology. 2015;17(5):708–17.CrossRefPubMedPubMedCentral
11.
Stupp R, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1100–8.CrossRefPubMed
12.
Chinot OL, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–22.CrossRefPubMed
13.
14.
Stupp R, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535–43.CrossRefPubMed
15.
Keime-Guibert F, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527–35.CrossRefPubMed
16.
Roa W, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583–8.CrossRefPubMed
17.
Tabatabai G, et al. Malignant astrocytoma in elderly patients: where do we stand? Curr Opin Neurol. 2013;26(6):693–700.CrossRefPubMed
18.
Wick W, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology. 2013;81(17):1515–22.CrossRefPubMed
19.
Malmstrom A, et al. Temozolomide versus standard 6‑week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–26.CrossRefPubMed
20.
Mason M, et al. Glioblastoma in the elderly: making sense of the evidence. Neurooncol Pract. 2016;3(2):77–86.
21.
22.
Shaw EG, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012;30(25):3065–70.CrossRefPubMedPubMedCentral
23.
24.
Baumert BG, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17(11):1521–32.CrossRefPubMed
25.
Reijneveld JC, et al. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17(11):1533–42.CrossRefPubMed
26.
27.
Metadata
Title
Milestones of the last 10 years
CNS cancer
Authors
Prof. Dr. Christine Marosi
a. Prof. Dr. Matthias Preusser
Publication date
01-02-2017
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2017
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0309-x

Other articles of this Issue 1/2017

memo - Magazine of European Medical Oncology 1/2017 Go to the issue

short review

Milestones in pathology—from histology to molecular biology

editorial

memo: Spectacular developments during the last decade from the Section Editors’ point of view

short review

Breast cancer milestones 2007–2016

short review

Milestones in Chronic Lymphocytic Leukemia

editorial

To print or not to print

short review

Milestones in the systemic treatment of lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits